JP2017519024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017519024A5 JP2017519024A5 JP2016574916A JP2016574916A JP2017519024A5 JP 2017519024 A5 JP2017519024 A5 JP 2017519024A5 JP 2016574916 A JP2016574916 A JP 2016574916A JP 2016574916 A JP2016574916 A JP 2016574916A JP 2017519024 A5 JP2017519024 A5 JP 2017519024A5
- Authority
- JP
- Japan
- Prior art keywords
- ester
- amide
- pharmaceutically acceptable
- acceptable salt
- hgdf15
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 41
- 150000001408 amides Chemical class 0.000 claims description 38
- 150000002148 esters Chemical class 0.000 claims description 38
- 150000004665 fatty acids Chemical class 0.000 claims description 22
- 125000005647 linker group Chemical group 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 14
- 229930195729 fatty acid Natural products 0.000 claims description 14
- 239000000194 fatty acid Substances 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 229940024606 amino acid Drugs 0.000 claims description 12
- 102000000597 Growth Differentiation Factor 15 Human genes 0.000 claims description 11
- 108010041834 Growth Differentiation Factor 15 Proteins 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 239000000178 monomer Substances 0.000 claims description 10
- 208000030159 metabolic disease Diseases 0.000 claims description 9
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 8
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 8
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 102000046181 human GDF15 Human genes 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims description 6
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims description 6
- 102000003729 Neprilysin Human genes 0.000 claims description 6
- 108090000028 Neprilysin Proteins 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- -1 histidine amino acids Chemical class 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 239000000539 dimer Substances 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims description 4
- 102100038495 Bile acid receptor Human genes 0.000 claims description 4
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims description 4
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims description 4
- 102000001267 GSK3 Human genes 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 4
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 102000004311 liver X receptors Human genes 0.000 claims description 4
- 108090000865 liver X receptors Proteins 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 229960005095 pioglitazone Drugs 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000002249 Diabetes Complications Diseases 0.000 claims description 3
- 206010012655 Diabetic complications Diseases 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 2
- 102100027824 3'(2'),5'-bisphosphate nucleotidase 1 Human genes 0.000 claims description 2
- MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940123208 Biguanide Drugs 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 229920001268 Cholestyramine Polymers 0.000 claims description 2
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 108010046163 Glycogen Phosphorylase Proteins 0.000 claims description 2
- 102000007390 Glycogen Phosphorylase Human genes 0.000 claims description 2
- 101001051973 Homo sapiens Fibroblast growth factor 23 Proteins 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims description 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims description 2
- IRLWJILLXJGJTD-UHFFFAOYSA-N Muraglitazar Chemical compound C1=CC(OC)=CC=C1OC(=O)N(CC(O)=O)CC(C=C1)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 IRLWJILLXJGJTD-UHFFFAOYSA-N 0.000 claims description 2
- 102400001095 Neuropeptide FF Human genes 0.000 claims description 2
- 208000007542 Paresis Diseases 0.000 claims description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 2
- 229940123934 Reductase inhibitor Drugs 0.000 claims description 2
- 102100037202 Sodium/myo-inositol cotransporter 2 Human genes 0.000 claims description 2
- 101710090560 Sodium/myo-inositol cotransporter 2 Proteins 0.000 claims description 2
- 102000018692 Sulfonylurea Receptors Human genes 0.000 claims description 2
- 108010091821 Sulfonylurea Receptors Proteins 0.000 claims description 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 2
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 2
- 229940000806 amaryl Drugs 0.000 claims description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 239000000883 anti-obesity agent Substances 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims description 2
- 229940125710 antiobesity agent Drugs 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 239000000496 cardiotonic agent Substances 0.000 claims description 2
- 125000003636 chemical group Chemical group 0.000 claims description 2
- YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims description 2
- 229950009226 ciglitazone Drugs 0.000 claims description 2
- QQKNSPHAFATFNQ-UHFFFAOYSA-N darglitazone Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCC(=O)C(C=C1)=CC=C1CC1SC(=O)NC1=O QQKNSPHAFATFNQ-UHFFFAOYSA-N 0.000 claims description 2
- 229950006689 darglitazone Drugs 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 229960001089 dobutamine Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229950002375 englitazone Drugs 0.000 claims description 2
- 229960002297 fenofibrate Drugs 0.000 claims description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 2
- 229940125753 fibrate Drugs 0.000 claims description 2
- 229960003883 furosemide Drugs 0.000 claims description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
- 229960004580 glibenclamide Drugs 0.000 claims description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical group O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 235000004554 glutamine Nutrition 0.000 claims description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 2
- 125000003827 glycol group Chemical group 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 235000014304 histidine Nutrition 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 239000004026 insulin derivative Substances 0.000 claims description 2
- 230000002473 insulinotropic effect Effects 0.000 claims description 2
- 239000002171 loop diuretic Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 235000006109 methionine Nutrition 0.000 claims description 2
- 229960003574 milrinone Drugs 0.000 claims description 2
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 claims description 2
- 230000003278 mimic effect Effects 0.000 claims description 2
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 claims description 2
- 229950001628 netoglitazone Drugs 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 2
- 229960001243 orlistat Drugs 0.000 claims description 2
- 210000002824 peroxisome Anatomy 0.000 claims description 2
- 108010055752 phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide Proteins 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 239000002461 renin inhibitor Substances 0.000 claims description 2
- 229940086526 renin-inhibitors Drugs 0.000 claims description 2
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims description 2
- 229960003015 rimonabant Drugs 0.000 claims description 2
- 229960004586 rosiglitazone Drugs 0.000 claims description 2
- 239000004059 squalene synthase inhibitor Substances 0.000 claims description 2
- CXGTZJYQWSUFET-IBGZPJMESA-N tesaglitazar Chemical compound C1=CC(C[C@H](OCC)C(O)=O)=CC=C1OCCC1=CC=C(OS(C)(=O)=O)C=C1 CXGTZJYQWSUFET-IBGZPJMESA-N 0.000 claims description 2
- 229950004704 tesaglitazar Drugs 0.000 claims description 2
- 229960005461 torasemide Drugs 0.000 claims description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001641 troglitazone Drugs 0.000 claims description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims 1
- 102000004279 Oxytocin receptors Human genes 0.000 claims 1
- 108090000876 Oxytocin receptors Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N C1CCCCC1 Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 229940122381 Oxytocin receptor agonist Drugs 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- DTLOVISJEFBXLX-REAFJZEQSA-N relexan 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@H]2CSSC[C@@H](C(=O)N[C@H](C(N1)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(O)=O)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DTLOVISJEFBXLX-REAFJZEQSA-N 0.000 description 1
- 229960002792 serelaxin Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462015862P | 2014-06-23 | 2014-06-23 | |
| US62/015,862 | 2014-06-23 | ||
| US201462082327P | 2014-11-20 | 2014-11-20 | |
| US62/082,327 | 2014-11-20 | ||
| US201562107016P | 2015-01-23 | 2015-01-23 | |
| US62/107,016 | 2015-01-23 | ||
| PCT/US2015/036328 WO2015200078A1 (en) | 2014-06-23 | 2015-06-18 | Fatty acids and their use in conjugation to biomolecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019140962A Division JP6823696B2 (ja) | 2014-06-23 | 2019-07-31 | 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017519024A JP2017519024A (ja) | 2017-07-13 |
| JP2017519024A5 true JP2017519024A5 (OSRAM) | 2018-07-12 |
| JP6636959B2 JP6636959B2 (ja) | 2020-01-29 |
Family
ID=53491695
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016574916A Active JP6636959B2 (ja) | 2014-06-23 | 2015-06-18 | 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用 |
| JP2019140962A Active JP6823696B2 (ja) | 2014-06-23 | 2019-07-31 | 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用 |
| JP2020152499A Expired - Fee Related JP7051959B2 (ja) | 2014-06-23 | 2020-09-11 | 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用 |
| JP2022054181A Ceased JP2022095757A (ja) | 2014-06-23 | 2022-03-29 | 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用 |
| JP2023074824A Active JP7650315B2 (ja) | 2014-06-23 | 2023-04-28 | 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019140962A Active JP6823696B2 (ja) | 2014-06-23 | 2019-07-31 | 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用 |
| JP2020152499A Expired - Fee Related JP7051959B2 (ja) | 2014-06-23 | 2020-09-11 | 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用 |
| JP2022054181A Ceased JP2022095757A (ja) | 2014-06-23 | 2022-03-29 | 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用 |
| JP2023074824A Active JP7650315B2 (ja) | 2014-06-23 | 2023-04-28 | 脂肪酸、および生体分子へのコンジュゲーションにおけるその使用 |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US10588980B2 (OSRAM) |
| EP (2) | EP3988170A1 (OSRAM) |
| JP (5) | JP6636959B2 (OSRAM) |
| KR (2) | KR20230056796A (OSRAM) |
| CN (3) | CN114099693A (OSRAM) |
| AP (1) | AP2016009585A0 (OSRAM) |
| AU (1) | AU2015280351C1 (OSRAM) |
| CA (1) | CA2953480A1 (OSRAM) |
| CL (1) | CL2016003281A1 (OSRAM) |
| CR (1) | CR20160596A (OSRAM) |
| CU (1) | CU24455B1 (OSRAM) |
| CY (1) | CY1125006T1 (OSRAM) |
| DK (1) | DK3157571T3 (OSRAM) |
| EA (1) | EA039074B1 (OSRAM) |
| EC (1) | ECSP17004665A (OSRAM) |
| ES (1) | ES2905479T3 (OSRAM) |
| GT (1) | GT201600263A (OSRAM) |
| HR (1) | HRP20220152T1 (OSRAM) |
| HU (1) | HUE057845T2 (OSRAM) |
| IL (1) | IL248990B (OSRAM) |
| JO (1) | JO3813B1 (OSRAM) |
| LT (1) | LT3157571T (OSRAM) |
| MA (1) | MA40278A (OSRAM) |
| MX (1) | MX367520B (OSRAM) |
| MY (1) | MY193993A (OSRAM) |
| PE (1) | PE20171095A1 (OSRAM) |
| PH (1) | PH12016502294B1 (OSRAM) |
| PL (1) | PL3157571T3 (OSRAM) |
| PT (1) | PT3157571T (OSRAM) |
| RS (1) | RS62907B1 (OSRAM) |
| SG (2) | SG11201609704TA (OSRAM) |
| SI (1) | SI3157571T1 (OSRAM) |
| TN (1) | TN2016000558A1 (OSRAM) |
| TW (3) | TWI701048B (OSRAM) |
| UY (1) | UY36186A (OSRAM) |
| WO (1) | WO2015200078A1 (OSRAM) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| EP2694092B1 (en) | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| JP6509852B2 (ja) | 2013-07-31 | 2019-05-08 | アムジエン・インコーポレーテツド | 増殖分化因子１５（ｇｄｆ−１５）の構築物 |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| KR20170084332A (ko) | 2014-12-04 | 2017-07-19 | 노파르티스 아게 | Klotho 변이체 폴리펩티드를 사용하는 방법 및 조성물 |
| PE20171328A1 (es) | 2015-01-23 | 2017-09-12 | Novartis Ag | Conjugados de acidos grasos y apelina sintetica con mayor vida media |
| JP6892433B2 (ja) | 2015-04-03 | 2021-06-23 | ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ | 十分に安定化された非対称ｓｉｒｎａ |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| JP6946304B2 (ja) | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| WO2017132669A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
| CA3025251A1 (en) | 2016-05-24 | 2017-11-30 | Novo Nordisk A/S | Mic-1 compounds and uses thereof |
| KR101727506B1 (ko) * | 2016-07-14 | 2017-05-04 | 충남대학교 산학협력단 | Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물 |
| US11753638B2 (en) | 2016-08-12 | 2023-09-12 | University Of Massachusetts | Conjugated oligonucleotides |
| RU2019126483A (ru) | 2017-01-23 | 2021-02-24 | Ридженерон Фармасьютикалз, Инк. | Варианты 17-бета-гидроксистероиддегидрогеназы 13 (hsd17b13) и их применение |
| WO2018148419A1 (en) | 2017-02-08 | 2018-08-16 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| CA3059348A1 (en) | 2017-04-11 | 2018-10-18 | Regeneron Pharmaceuticals, Inc. | Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family |
| ES2867807T3 (es) | 2017-04-24 | 2021-10-20 | Igm Group B V | Proceso para la preparación de cetonas a-funcionalizadas |
| WO2018213082A1 (en) * | 2017-05-18 | 2018-11-22 | Regeneron Pharmaceuticals, Inc. | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof |
| TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| JP7406793B2 (ja) | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 |
| KR102694809B1 (ko) | 2017-10-11 | 2024-08-16 | 리제너론 파마슈티칼스 인코포레이티드 | Pnpla3 i148m 변이를 발현하는 환자의 간 질환의 치료에서의 hsd17b13의 저해 |
| CN119386162A (zh) * | 2017-12-22 | 2025-02-07 | 诺华股份有限公司 | 用fgf21变体治疗代谢障碍的方法 |
| MX2020009812A (es) | 2018-03-21 | 2021-01-08 | Regeneron Pharma | COMPOSICIONES DE ARNI DE 17ß-HIDROXIESTEROIDE DESHIDROGENASA TIPO 13 (HSD17B13) Y MÉTODOS DE USO DE LAS MISMAS. |
| WO2019179494A1 (zh) * | 2018-03-23 | 2019-09-26 | 深圳市塔吉瑞生物医药有限公司 | 取代的十五烷二酸化合物及药物组合物及其用途 |
| CA3096097A1 (en) | 2018-04-09 | 2019-10-17 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
| JP7398396B2 (ja) | 2018-06-01 | 2023-12-14 | ノバルティス アーゲー | Ｂｃｍａに対する結合分子及びその使用 |
| AU2019316640A1 (en) | 2018-08-10 | 2021-03-18 | University Of Massachusetts | Modified oligonucleotides targeting SNPs |
| EP3833974A2 (en) | 2018-08-10 | 2021-06-16 | Novartis AG | Gfral extracellular domains and methods of use |
| US11279930B2 (en) | 2018-08-23 | 2022-03-22 | University Of Massachusetts | O-methyl rich fully stabilized oligonucleotides |
| TWI869213B (zh) * | 2018-09-19 | 2025-01-01 | 美商Ionis製藥公司 | Pnpla3表現之調節劑 |
| EA202191105A1 (ru) * | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
| US20220025344A1 (en) | 2018-11-26 | 2022-01-27 | Novartis Ag | Lpl-gpihbp1 fusion polypeptides |
| CA3125441A1 (en) | 2019-01-18 | 2020-07-23 | University Of Massachusetts | Dynamic pharmacokinetic-modifying anchors |
| US20230053119A1 (en) * | 2019-04-23 | 2023-02-16 | Lg Chem, Ltd. | FUSION POLYPEPTIDE COMPRISING Fc REGION OF IMMUNOGLOBULIN AND GDF15 |
| CN111909256A (zh) * | 2019-05-10 | 2020-11-10 | 宁波鲲鹏生物科技有限公司 | 多肽衍生物及其制备方法 |
| EP3972998A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Cd19 binding molecules and uses thereof |
| EP3972993A1 (en) | 2019-05-21 | 2022-03-30 | Novartis AG | Variant cd58 domains and uses thereof |
| WO2021016043A1 (en) * | 2019-07-19 | 2021-01-28 | Inari Agriculture, Inc. | Improved homology dependent repair genome editing |
| CA3149835A1 (en) | 2019-08-09 | 2021-02-18 | University Of Massachusetts | Chemically modified oligonucleotides targeting snps |
| JP7672394B2 (ja) * | 2019-09-03 | 2025-05-07 | アークトゥラス・セラピューティクス・インコーポレイテッド | 治療的に活性な複合体のアシアロ糖タンパク質受容体媒介送達 |
| US12365894B2 (en) | 2019-09-16 | 2025-07-22 | University Of Massachusetts | Branched lipid conjugates of siRNA for specific tissue delivery |
| EP4041281B1 (en) | 2019-10-04 | 2025-11-26 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| JP2023500763A (ja) | 2019-11-04 | 2023-01-11 | フェリング ベスローテン フェンノートシャップ | 泌乳の改善のためのメロトシンの鼻腔内投与 |
| JP2023503722A (ja) * | 2019-11-26 | 2023-01-31 | ディー・ティー・エックス・ファーマ・インコーポレイテッド | 核酸および半減期モチーフを含む化合物 |
| WO2021126990A1 (en) * | 2019-12-16 | 2021-06-24 | The Scripps Research Institute | Oxytocin derivatives with improved properties |
| CN116925237A (zh) | 2019-12-31 | 2023-10-24 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| WO2021144314A1 (en) * | 2020-01-13 | 2021-07-22 | Synaffix B.V. | Via cycloaddition bilaterally functionalized antibodies |
| WO2021144313A1 (en) * | 2020-01-13 | 2021-07-22 | Synaffix B.V. | Via cycloaddition bilaterally functionalized antibodies |
| CN115768483A (zh) * | 2020-01-13 | 2023-03-07 | 西纳福克斯股份有限公司 | 抗体与免疫细胞衔接器的缀合物 |
| IL302569A (en) | 2020-11-06 | 2023-07-01 | Novartis Ag | Cd19 binding molecules and uses thereof |
| KR102543789B1 (ko) * | 2021-03-08 | 2023-06-20 | 주식회사 온코크로스 | 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물 |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| TW202304500A (zh) | 2021-04-21 | 2023-02-01 | 瑞士商諾華公司 | 升糖素樣肽化合物 |
| EP4351628A4 (en) * | 2021-05-21 | 2025-06-04 | Yuhan Corporation | COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE OR NON-ALCOHOLIC STEATOHEPATITIS COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT |
| CA3174095A1 (en) | 2021-06-23 | 2022-12-29 | Vignesh Narayan HARIHARAN | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
| CA3231700A1 (en) * | 2021-09-10 | 2023-03-16 | Guardian Therapeutics, Llc | Fatty acid conjugates of nucleic acids |
| CN113582832B (zh) * | 2021-09-13 | 2024-01-26 | 深圳瑞德林生物技术有限公司 | 一种长链二酸的制备方法 |
| JP2025505198A (ja) | 2022-02-10 | 2025-02-21 | ノバルティス アーゲー | 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体 |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
| CN114740105B (zh) * | 2022-03-17 | 2023-11-07 | 重庆医药高等专科学校 | 一种脯氨酸和n-甲基脯氨酸的液相色谱分离检测方法及其应用 |
| WO2023196754A2 (en) * | 2022-04-08 | 2023-10-12 | University Of North Texas Health Science Center At Fort Worth | Treatment for reducing or preventing tissue fibrosis |
| CN114891086B (zh) * | 2022-06-01 | 2024-03-26 | 恺佧生物科技(上海)有限公司 | 一种生物素标记的gdf15的复性方法 |
| JP2025525172A (ja) * | 2022-08-01 | 2025-08-01 | ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | プロピオン酸血漿、メチルマロン酸尿症、およびエネルギー代謝障害の治療に使用するためのアナプレロティック化合物としての脂肪酸－ｄ－アミノ酸ペプチド複合体 |
| CN115575539B (zh) * | 2022-10-12 | 2025-04-18 | 南方医科大学珠江医院 | 一种生物标本中短链脂肪酸及其羟基化衍生物的检测方法 |
| CN116789764B (zh) * | 2023-05-30 | 2025-01-03 | 北京悦康科创医药科技股份有限公司 | 一种抗冠状病毒多肽的制备方法 |
| CN116466010B (zh) * | 2023-06-15 | 2023-08-25 | 四川普锐特药业有限公司 | 一种用于脂质纳米粒中多种脂质组分定量检测的方法 |
| WO2025049634A1 (en) * | 2023-08-29 | 2025-03-06 | Ganna Bio, Inc. | Glycan conjugate compositions and methods |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3043871A (en) * | 1956-09-03 | 1962-07-10 | Ruhrchemie Ag | Production of heptadecanedicarboxylic acid-1, 17 |
| EP0112344A1 (en) | 1982-06-11 | 1984-07-04 | National Research Development Corporation | Amphipathic compounds |
| US4517105A (en) | 1983-03-07 | 1985-05-14 | Aluminum Company Of America | Metalworking lubricant composition containing a novel substituted malonic acid diester |
| US4582927A (en) | 1984-04-04 | 1986-04-15 | Frito-Lay, Inc. | Synthetic cooking oils containing dicarboxylic acid esters |
| US5175191A (en) | 1988-11-14 | 1992-12-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| EP0492628B1 (en) | 1990-12-26 | 1996-07-03 | Ricoh Company, Ltd | Reversible thermosensitive coloring composition, recording medium, recording method and image display apparatus using the recording medium |
| US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| AU1830195A (en) | 1994-12-15 | 1996-07-03 | Human Genome Sciences, Inc. | Prostatic growth factor |
| US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| FR2735131B1 (fr) | 1995-06-12 | 1997-08-22 | Rech De Pathologie Appliquee S | Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament |
| DE69637844D1 (de) | 1995-06-22 | 2009-04-09 | St Vincent S Hospital Sidney L | Neues tgf-beta-ahnliches cytokin |
| US20020052310A1 (en) | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
| EP0950105A1 (en) | 1996-09-11 | 1999-10-20 | Ortho-McNeil Pharmaceutical, Inc. | Tnf-beta-like protein for treating prostate cancer, and related nucleic acid molecules, pharmaceutical compositions and methods |
| AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
| ATE383424T1 (de) | 1997-12-24 | 2008-01-15 | Takeda Pharmaceutical | Polypeptide, deren herstellung und verwendung |
| US6974684B2 (en) | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| US6297400B1 (en) | 1999-07-02 | 2001-10-02 | The Clorox Company | Synthesis of a tetraamido macrocycle ligand from a novel diamidodiol |
| US20020045170A1 (en) | 2000-04-06 | 2002-04-18 | Wong Gordon G. | Polynucleotides encoding novel secreted proteins |
| AU5018201A (en) | 2000-04-20 | 2001-11-07 | St Vincents Hospital Sydney Lt | Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1) |
| EP1456360B1 (en) | 2001-04-19 | 2015-06-03 | The Scripps Research Institute | Methods and composition for the production of orthoganal trna-aminoacyltrna synthetase pairs |
| US20030166903A1 (en) | 2001-04-27 | 2003-09-04 | Anna Astromoff | Genes associated with vascular disease |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| US7157235B2 (en) | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
| US7652061B2 (en) | 2003-05-20 | 2010-01-26 | Novartis A.G. | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors |
| JP4949838B2 (ja) | 2003-09-19 | 2012-06-13 | ノヴォ ノルディスク アー／エス | 新規ｇｌｐ−１誘導体 |
| JP2007522803A (ja) | 2004-01-14 | 2007-08-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ペルオキシソーム増殖因子活性化受容体アルファ標的遺伝子を使用する方法 |
| ES2555956T3 (es) | 2004-04-13 | 2016-01-11 | St Vincent's Hospital Sydney Limited | Método para modular el apetito |
| WO2005099747A1 (en) | 2004-04-14 | 2005-10-27 | Medical Research Council | Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6 |
| US8431558B2 (en) | 2004-11-01 | 2013-04-30 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
| EP1877426B1 (en) | 2005-04-29 | 2012-02-01 | GlaxoSmithKline Biologicals SA | Method for preventing or treating m tuberculosis infection |
| US20110319324A1 (en) | 2005-05-27 | 2011-12-29 | Five Prime Therapeutics, Inc. | Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases |
| US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
| WO2007062526A1 (en) | 2005-11-30 | 2007-06-07 | Ambrilia Biopharma Inc. | Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation |
| CN101584858A (zh) | 2005-12-20 | 2009-11-25 | 布里斯托尔-迈尔斯斯奎布公司 | 稳定蛋白质制剂 |
| CN101002945B (zh) * | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
| JP2010536717A (ja) | 2007-08-16 | 2010-12-02 | セントビンセンツ ホスピタル シドニー リミテッド | マクロファージ阻害性サイトカイン（ｍｉｃ−１）活性を調節するための作用物質及び方法 |
| WO2009042798A1 (en) | 2007-09-26 | 2009-04-02 | Cold Spring Harbor Laboratory | Methods for treating fibrosis by modulating cellular senescence |
| US8420088B2 (en) | 2008-01-28 | 2013-04-16 | Novartis Ag | Methods and compositions using FGF23 fusion polypeptides |
| TW200936156A (en) | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| PT2260053E (pt) | 2008-03-31 | 2014-08-29 | Ferring Bv | Análogos de oxitocina |
| EA021001B1 (ru) | 2008-10-24 | 2015-03-31 | Новартис Аг | Биосинтетический пирролинкарбоксилизин и сайт-специфичные модификации белка за счет химической модификации остатков пирролинкарбоксилизина и пирролизина |
| WO2010052144A2 (en) * | 2008-11-05 | 2010-05-14 | F. Hoffmann-La Roche Ag | Neuropeptide-2-receptor (y-2r) agonists and uses thereof |
| EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
| EP2211182A1 (en) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Method for the assessment of severity of liver cirrhosis |
| EP2261662B1 (en) * | 2009-06-10 | 2014-01-22 | Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften | Novel synthetic blocking reagents |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| EP2521446A2 (en) | 2010-01-06 | 2012-11-14 | The University of North Carolina At Chapel Hill | Fatty acid derivatives and analogs of drugs |
| CN101852804B (zh) | 2010-03-29 | 2013-06-12 | 中国医学科学院病原生物学研究所 | Gdf15蛋白的抗体的新用途 |
| PL2563753T6 (pl) | 2010-04-27 | 2016-05-31 | Synaffix Bv | Stopione związki cyklooktynu i ich zastosowanie w reakcjach typu "click" bez udziału metalu |
| CN102869259A (zh) * | 2010-04-27 | 2013-01-09 | 先正达参股股份有限公司 | 控制耐新烟碱的蚜虫的方法 |
| CN103124788B (zh) | 2010-05-21 | 2016-01-13 | 梅里麦克制药股份有限公司 | 双特异性融合蛋白 |
| GB201018518D0 (en) * | 2010-11-03 | 2010-12-15 | Univ Leuven Kath | Novel endolysin |
| EP2694092B1 (en) | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| US9480751B2 (en) | 2011-04-11 | 2016-11-01 | Yeda Research And Development Co. Ltd. | Albumin binding probes and drug conjugates thereof |
| WO2013006656A2 (en) | 2011-07-05 | 2013-01-10 | The Regents Of The University Of California | Appetite stimulating protein |
| WO2013027191A1 (en) | 2011-08-25 | 2013-02-28 | Novartis Ag | Methods and compositions using fgf23 fusion polypeptides |
| KR20140125803A (ko) | 2012-01-26 | 2014-10-29 | 암젠 인크 | 성장 분화 인자 15(gdf-15) 폴리펩타이드들 |
| MX366864B (es) | 2012-02-27 | 2019-07-26 | Amunix Operating Inc | Composiciones de conjugados de xten y métodos para realizarlas. |
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| US8921307B2 (en) | 2012-11-20 | 2014-12-30 | Novartis Ag | Synthetic linear apelin mimetics for the treatment of heart failure |
| ES2732574T3 (es) | 2012-11-30 | 2019-11-25 | Novartis Ag | Métodos para preparar conjugados a partir de proteínas que contienen disulfuro |
| DK2935312T3 (en) | 2012-12-21 | 2018-10-22 | Hoffmann La Roche | Peptides as oxytocin agonists |
| CN105073133B (zh) | 2012-12-21 | 2021-04-20 | Aveo制药公司 | 抗gdf15抗体 |
| RU2704285C2 (ru) | 2013-01-30 | 2019-10-25 | Нгм Байофармасьютикалз, Инк. | Композиции и способы применения для лечения метаболических расстройств |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| AU2014262843B2 (en) | 2013-05-06 | 2017-06-22 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| SG10201906172XA (en) | 2013-07-03 | 2019-08-27 | Alder Biopharmaceuticals Inc | Regulation of glucose metabolism using anti-cgrp antibodies |
| KR20160040556A (ko) | 2013-07-11 | 2016-04-14 | 노파르티스 아게 | 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형 |
| BR112016001542A2 (pt) | 2013-07-25 | 2017-08-29 | Novartis Ag | Polipeptídios cíclicos para o tratamento de insuficiência cardíaca |
| BR112016001376A2 (pt) | 2013-07-25 | 2017-10-24 | Novartis Ag | bioconjugados de polipeptídeos de apelin sintéticos |
| JP6505691B2 (ja) | 2013-07-25 | 2019-04-24 | ノバルティス アーゲー | 心不全治療用の環状アペリン誘導体 |
| US9683018B2 (en) | 2013-07-25 | 2017-06-20 | Novartis Ag | Disulfide cyclic polypeptides for the treatment of heart failure |
| JP6509852B2 (ja) | 2013-07-31 | 2019-05-08 | アムジエン・インコーポレーテツド | 増殖分化因子１５（ｇｄｆ−１５）の構築物 |
| WO2015079376A1 (en) | 2013-11-26 | 2015-06-04 | Novartis Ag | Methods for oxime conjugation to ketone-modified polypeptides |
| AU2015213721B2 (en) | 2014-02-07 | 2021-05-20 | Effector Therapeutics, Inc. | Methods for treating fibrotic disease |
| JP6329626B2 (ja) | 2014-05-01 | 2018-05-23 | 富士フイルム株式会社 | 赤外線センサ、近赤外線吸収組成物、感光性樹脂組成物、化合物、近赤外線吸収フィルタおよび撮像装置 |
| CA2947967A1 (en) | 2014-05-06 | 2015-11-12 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| US10406198B2 (en) | 2014-05-23 | 2019-09-10 | Novartis Ag | Methods for making conjugates from disulfide-containing proteins |
| EP3157953B1 (en) | 2014-06-20 | 2021-12-22 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| JP6675333B2 (ja) | 2014-06-23 | 2020-04-01 | ノバルティス アーゲー | 部位特異的タンパク質修飾 |
| RU2017101436A (ru) | 2014-06-24 | 2018-07-24 | Ново Нордиск А/С | Mic-1 слитные белки и их применение |
| SG10201802098UA (en) | 2014-07-30 | 2018-04-27 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
| US10603359B2 (en) | 2014-10-30 | 2020-03-31 | Acceleron Pharma Inc. | Methods and compositions using GDF15 polypeptides for increasing red blood cells |
| CN115043945A (zh) | 2014-10-31 | 2022-09-13 | Ngm生物制药有限公司 | 用于治疗代谢病症的组合物和方法 |
| JP2018502908A (ja) | 2014-12-22 | 2018-02-01 | ノヴォ ノルディスク アー／エス | アルファ‐１‐ アンチトリプシン（ａ１ａｔ）融合タンパク質及びその使用 |
| PE20171328A1 (es) | 2015-01-23 | 2017-09-12 | Novartis Ag | Conjugados de acidos grasos y apelina sintetica con mayor vida media |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| CN113683708A (zh) | 2015-04-06 | 2021-11-23 | 阿塞勒隆制药公司 | 单臂i型和ii型受体融合蛋白和其用途 |
| MA53400A (fr) | 2015-04-06 | 2021-08-04 | Acceleron Pharma Inc | Hétéromultimères alk7: actriib et leurs utilisations |
| WO2017066525A1 (en) | 2015-10-14 | 2017-04-20 | The Johns Hopkins University | Protein bioconjugation method |
| JP6946304B2 (ja) | 2015-12-22 | 2021-10-06 | ノバルティス アーゲー | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
| EP3184106A1 (en) | 2015-12-23 | 2017-06-28 | Sanofi-Aventis Deutschland GmbH | Growth differentiation factor 15 as biomarker for metformin |
| US11105818B2 (en) | 2016-01-15 | 2021-08-31 | Novo Nordisk A/S | MIC-1 receptor and uses thereof |
| JP2019510739A (ja) | 2016-02-29 | 2019-04-18 | イーライ リリー アンド カンパニー | Ｇｆｒａｌ受容体療法 |
| AU2017228489A1 (en) | 2016-03-04 | 2018-09-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| KR101727506B1 (ko) | 2016-07-14 | 2017-05-04 | 충남대학교 산학협력단 | Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물 |
| EP3612558A1 (en) | 2017-04-20 | 2020-02-26 | Novo Nordisk A/S | Methods of purification of albumin fusion proteins |
| TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| WO2019048660A1 (en) | 2017-09-10 | 2019-03-14 | Novo Nordisk A/S | MIC-1 AND GLP-1 FOR USE IN THE TREATMENT OF OBESITY |
| WO2020185533A1 (en) | 2019-03-08 | 2020-09-17 | Amgen Inc. | Growth differentiation factor 15 combination therapy |
| EP4041281B1 (en) | 2019-10-04 | 2025-11-26 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| CN116925237A (zh) | 2019-12-31 | 2023-10-24 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| CN115916239A (zh) | 2020-04-15 | 2023-04-04 | 治疗调适公司 | 用于靶向治疗性递送至骨的组合物和方法 |
| WO2022092915A1 (ko) | 2020-10-30 | 2022-05-05 | 가톨릭대학교 산학협력단 | Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물 |
-
2015
- 2015-06-12 US US14/738,272 patent/US10588980B2/en active Active
- 2015-06-18 WO PCT/US2015/036328 patent/WO2015200078A1/en not_active Ceased
- 2015-06-18 RS RS20220111A patent/RS62907B1/sr unknown
- 2015-06-18 LT LTEPPCT/US2015/036328T patent/LT3157571T/lt unknown
- 2015-06-18 CN CN202111265377.6A patent/CN114099693A/zh active Pending
- 2015-06-18 KR KR1020237013073A patent/KR20230056796A/ko not_active Ceased
- 2015-06-18 KR KR1020177001520A patent/KR102559975B1/ko active Active
- 2015-06-18 CU CU2016000189A patent/CU24455B1/es unknown
- 2015-06-18 MY MYPI2016704254A patent/MY193993A/en unknown
- 2015-06-18 PL PL15732508T patent/PL3157571T3/pl unknown
- 2015-06-18 SG SG11201609704TA patent/SG11201609704TA/en unknown
- 2015-06-18 HU HUE15732508A patent/HUE057845T2/hu unknown
- 2015-06-18 EA EA201692466A patent/EA039074B1/ru unknown
- 2015-06-18 HR HRP20220152TT patent/HRP20220152T1/hr unknown
- 2015-06-18 PE PE2016002771A patent/PE20171095A1/es unknown
- 2015-06-18 JP JP2016574916A patent/JP6636959B2/ja active Active
- 2015-06-18 CN CN201580033910.2A patent/CN107073130B/zh active Active
- 2015-06-18 SI SI201531787T patent/SI3157571T1/sl unknown
- 2015-06-18 MA MA040278A patent/MA40278A/fr unknown
- 2015-06-18 AU AU2015280351A patent/AU2015280351C1/en active Active
- 2015-06-18 PT PT157325085T patent/PT3157571T/pt unknown
- 2015-06-18 TN TN2016000558A patent/TN2016000558A1/en unknown
- 2015-06-18 ES ES15732508T patent/ES2905479T3/es active Active
- 2015-06-18 EP EP21206196.4A patent/EP3988170A1/en active Pending
- 2015-06-18 SG SG10201912965TA patent/SG10201912965TA/en unknown
- 2015-06-18 AP AP2016009585A patent/AP2016009585A0/en unknown
- 2015-06-18 CN CN202111296952.9A patent/CN114133443A/zh active Pending
- 2015-06-18 EP EP15732508.5A patent/EP3157571B1/en active Active
- 2015-06-18 DK DK15732508.5T patent/DK3157571T3/da active
- 2015-06-18 CA CA2953480A patent/CA2953480A1/en active Pending
- 2015-06-18 MX MX2016017395A patent/MX367520B/es active IP Right Grant
- 2015-06-18 CR CR20160596A patent/CR20160596A/es unknown
- 2015-06-21 JO JOP/2015/0150A patent/JO3813B1/ar active
- 2015-06-22 TW TW104120074A patent/TWI701048B/zh active
- 2015-06-22 TW TW109123095A patent/TWI750725B/zh active
- 2015-06-22 UY UY0001036186A patent/UY36186A/es unknown
- 2015-06-22 TW TW110136772A patent/TWI792596B/zh not_active IP Right Cessation
-
2016
- 2016-11-15 IL IL248990A patent/IL248990B/en active IP Right Grant
- 2016-11-17 PH PH12016502294A patent/PH12016502294B1/en unknown
- 2016-12-21 CL CL2016003281A patent/CL2016003281A1/es unknown
- 2016-12-22 GT GT201600263A patent/GT201600263A/es unknown
-
2017
- 2017-01-25 EC ECIEPI20174665A patent/ECSP17004665A/es unknown
-
2018
- 2018-05-21 US US15/985,060 patent/US10786576B2/en active Active
-
2019
- 2019-07-31 JP JP2019140962A patent/JP6823696B2/ja active Active
-
2020
- 2020-06-01 US US16/889,201 patent/US11752211B2/en active Active
- 2020-09-11 JP JP2020152499A patent/JP7051959B2/ja not_active Expired - Fee Related
-
2022
- 2022-02-22 CY CY20221100152T patent/CY1125006T1/el unknown
- 2022-03-29 JP JP2022054181A patent/JP2022095757A/ja not_active Ceased
-
2023
- 2023-04-28 JP JP2023074824A patent/JP7650315B2/ja active Active
- 2023-07-14 US US18/352,345 patent/US20240066132A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017519024A5 (OSRAM) | ||
| US11111285B2 (en) | Glucagon-GLP-1-GIP triple agonist compounds | |
| US11008375B2 (en) | GIP-GLP-1 dual agonist compounds and methods | |
| US11814417B2 (en) | GIP agonist compounds and methods | |
| HRP20220152T1 (hr) | Masne kiseline i njihova upotreba u konjugaciji s biomolekulama | |
| ES3011982T3 (en) | Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof | |
| KR102394515B1 (ko) | 아실화된 글루카곤 유사체 | |
| US10766939B2 (en) | Amylin analogues | |
| US11167014B2 (en) | Solid glp-1 derivative compositions for oral administration | |
| US9259477B2 (en) | GLP-1 receptor agonist peptide gastrin conjugates | |
| TW201412769A (zh) | 升糖素類似物 | |
| JP2010535714A (ja) | 長期間作用性ペプチド類似体のための組成物 | |
| US20180009849A1 (en) | Ghrelin analogues | |
| ES3041327T3 (en) | Liquid formulations of glucagon analogues | |
| US20240424072A1 (en) | Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor | |
| AU2024306568A9 (en) | Albumin bound macromolecule tri-agonist activating glp-1/gip/glucagon receptors and methods therefor | |
| CN105658234A (zh) | 拟胰岛淀粉样多肽化合物与聚乙二醇的非-凝聚生物缀合物 | |
| FR3084586A1 (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes | |
| TW202535451A (zh) | 經修飾之調酸素及其使用方法 |